Ligand Pharmaceuticals stock is on the rise with optimistic analyst ratings and a plan for 20% annual revenue growth. Learn ...

While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

减肥药物赛道的竞争异常激烈，但华尔街对一家名为Viking Therapeutics（NASDAQ: ...

The NFL's decision to move the Rams-Vikings game marks just the second time the league's moved a playoff game in its 105-season history. While Monday's game is being moved for safety concerns ...

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other stocks that ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $33.69, moving +0.78% from the previous trading session.

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Hedge fund founder George Weiss filed a defamation suit in New York against Jefferies Financial (JEF), alleging the bank engaged in a “smear ...